Similar levels of TNFα, IL-1β, and IL-6 were also observed in those NAFLD patients who tested positive for SIBO compared to healthy controls (8.39 ± 0.56 vs. 7.8 ± 0.01, p = 0.240; 11.66 ± 5.55 vs. 6.26 ± 2.76, p = 0.362; and 3.12 ± 0.05 vs. 3.14 ± 0.10, p = 0.372, respectively). This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.